{"prompt": "['Product: MK-3475', '53', 'Protocol/Amendment No.: 604-09', 'Dose may be rounded to the nearest 50 mg at the discretion of the investigator, and according', 'to institutional standards.', 'Unless there is a change in weight >10%, the same dose of carboplatin can be used', 'throughout the 4 cycles (provided there are no additional toxicities).', 'Additional premedications should be administered as per standard practice.', '5.2.2.2.2 Cisplatin', 'Cisplatin 75 mg/m\u00b2 will be administered as an IV infusion Q3W on Day 1 for 4 cycles. An', 'infusion time of 60 minutes is recommended, but cisplatin may be administered over 30 to', '180 minutes to accommodate local SOCs. Body surface area (BSA) will be obtained using', 'the Dubois and Dubois or Mosteller formula. The BSA calculated on Cycle 1, Day 1 of', 'therapy can be used throughout the 4 cycles, unless there is a change in weight >10%.', 'Cisplatin will be given for up to 4 cycles. Additional premedications should be administered', 'as per standard practice.', '5.2.2.2.3 Etoposide', 'Etoposide 100 mg/m\u00b2 will be administered as an IV infusion Q3W on Days 1, 2, and 3 of', 'Cycles 1 to 4. Days 1, 2, and 3 must be consecutive days without interruption. An infusion', 'time of 30 to 60 minutes is recommended, but etoposide may be administered over 30 to', '120 minutes to accommodate local standards of care. Body surface area will be obtained', 'using the Dubois and Dubois or Mosteller formula. The BSA calculated on Cycle 1, Day 1 of', 'therapy can be used throughout the 4 cycles, unless there is a change in weight >10%.', 'Additional premedications should be administered as per standard practice.', '5.2.3 Trial Blinding', 'This is a double-blinded trial with respect to pembrolizumab and placebo treatment. The', 'subject, the investigator, and Sponsor personnel or delegate(s) who are involved in the', 'treatment administration or clinical evaluation of the subjects will be unaware of the', 'treatment assignments. The chemotherapy agents will be open-label. Pembrolizumab will be', \"supplied to the sites in an open label manner. The study site's unblinded pharmacist will\", \"obtain each subject's study identification number and study drug assignment from the\", 'interactive voice response system/integrated web response system (IVRS/IWRS) and prepare', 'the solutions for infusion. The unblinded pharmacist will provide the investigative staff with', 'ready-to-use blinded pembrolizumab or saline placebo infusion solutions, packaged', 'identically in order to maintain the blinding, for administration at scheduled infusion visits.', 'In addition to emergency unblinding for severe or life-threatening AEs with potential', 'immunologic etiology, non-emergency unblinding to pembrolizumab versus placebo', 'administration may occur on an individual subject basis and only after consultation with the', 'Sponsor at the time of (1) centrally verified disease progression and subject has discontinued', 'all study treatments or, (2) when the subject has discontinued all study treatments and a new', 'anti-cancer treatment is going to be started. Non-emergency unblinding, only after', 'MK-3475-604-09 Final Protocol', '23-Apr-2019', 'Confidential']['Product: MK-3475', '54', 'Protocol/Amendment No.: 604-09', 'consultation and approval from the Sponsor, is implemented through interactive response', 'technology (IRT) by following the instructions in the IRT site user manual.', 'Additionally, imaging data will be centrally reviewed by radiologists who are blinded to', 'subject treatment assignment, and the allocation schedule will be blinded in the database,', 'preventing aggregate analysis.', 'See Section 7.1.4.2, Blinding/Unblinding, for a description of the method of unblinding a', 'subject during the trial, should such action be warranted.', '5.3 Randomization', 'Treatment randomization will occur centrally using an interactive voice response system /', 'integrated web response system (IVRS/IWRS). There are 2 treatment arms. Subjects will be', 'assigned randomly in a 1:1 ratio to pembrolizumab + EP or placebo + EP. Prior to', \"randomization, the investigator's choice of platinum agent (cisplatin or carboplatin) will be\", 'documented in the IVRS/IWRS system.', '5.4 Stratification', 'Treatment randomization will be stratified according to the following factors:', 'Type of platinum therapy (carboplatin or cisplatin)', 'Baseline ECOG performance status (0 or 1)', 'Baseline LDH (< or >ULN)', '5.5', 'Concomitant Medications/Vaccinations (Allowed & Prohibited)', 'Medications or vaccinations specifically prohibited in the exclusion criteria are not allowed', 'during the ongoing trial. If there is a clinical indication for any medication or vaccination', 'specifically prohibited during the trial, discontinuation from trial therapy or vaccination may', 'be required. The investigator should discuss any questions regarding this with the Sponsor', 'Clinical Director. The final decision on any supportive therapy or vaccination rests with the', \"investigator and/or the subject's primary physician. However, the decision to continue the\", 'subject on trial therapy or vaccination schedule requires the mutual agreement of the', 'investigator, the Sponsor and the subject.', '5.5.1 Acceptable Concomitant Medications', \"All treatments that the investigator considers necessary for a subject's welfare may be\", 'administered at the discretion of the investigator in keeping with the community standards of', 'medical care. All concomitant medications will be recorded on the electronic case report', 'form (eCRF) including all prescription, over-the-counter (OTC), herbal supplements, and IV', 'medications and fluids. If changes occur during the trial period, documentation of drug', 'dosage, frequency, route, and date will also be included on the eCRF.', 'MK-3475-604-09 Final Protocol', '23-Apr-2019', 'Confidential']\n\n###\n\n", "completion": "END"}